This week in Phispers, we bring you news on the Singh brothers, the former promoters of Ranbaxy, who lost a case in the Delhi high court, and will now have to pay US$ 550 million to Japanese drugmaker Daiichi Sankyo. There is an update on investigations into the deaths of Apotex founder Barry Sherman and his wife, even as the company goes through a churn at the top. In June 2017, the USFDA had ruled that generics relying on data from Semler Research are not considered equivalent to the brand. Now, Semler has sued the FDA for ‘annihilating its business’. Meanwhile, the M&A frenzy continued as Sanofi snapped up another biotech firm — Ablynx — for US$ 4.8 billion. The USFDA approved AAA’s Lutathera; and J&J opted out of the race for Pfizer’s US$ 20 billion consumer unit.
HC allows Daiichi to recover US$ 551 million from Ranbaxy’s Singh brothers
This has been a terrible week for the former promoters of Ranbaxy Laboratories — Malvinder and Shivender Singh. First there was news that a New York-based investor has filed a lawsuit in the Delhi High Court accusing the duo of “